Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CN 105

Next Previous
Drug Profile

CN 105

Alternative Names: Ac-VSRRR-NH2; CN-105

Latest Information Update: 16 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CereNova
  • Developer AegisCN
  • Class Anti-inflammatories; Antihaemorrhagics; Apolipoprotein therapeutics; Neuropeptides; Neuroprotectants; Peptides; Small molecules
  • Mechanism of Action Apolipoprotein E agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cerebral haemorrhage

Most Recent Events

  • 30 Jun 2019 AegisCN completes a phase II trial in Cerebral haemorrhage in USA (NCT03168581)
  • 26 Oct 2018 Aegis CN in collaboration with National Neuroscience Institute plans the phase II S-CATCH trial in Cerebral haemorrhage in November 2018 (NCT03711903)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top